Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruiting
NCT07166601Phase 1Updated Aug 11, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumor
United States, Canada, Japan
"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine UptakeActive Not Recruiting
NCT06587243NAUpdated Aug 10, 2026
Sponsor: Johns Hopkins Bloomberg School of Public Health
Vaccination
United States
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Active Not Recruiting
NCT05382325Phase 1Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors
United States, Canada, Israel, Netherlands
Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)Terminated
NCT06161116Phase 2Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Canada, Chile +12 more
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Recruiting
NCT07340827Phase 3Updated Aug 10, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Infertility
Japan
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Recruiting
NCT07405164Phase 3Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Von Hippel-Lindau Disease · Malignant Neoplasms
United States, Australia, Belgium, Brazil, Chile +16 more
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Recruiting
NCT07486960Phase 2Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Psoriatic Arthritis
United States, Canada, Chile, Colombia, Germany +3 more
SW-682 in Advanced Solid TumorsRecruiting
NCT06251310Phase 1Updated Aug 10, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor · Mesothelioma, Malignant
United States
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Recruiting
NCT07266831Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
United States, Argentina, Canada, Chile, France +4 more
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Recruiting
NCT04585750Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: PMV Pharmaceuticals, Inc
Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer · Metastatic Solid Tumor
United States, Australia, France, Germany, Italy +4 more
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)Recruiting
NCT07247110Phase 1Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Australia, Canada, Chile, Israel +2 more
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityCompleted
NCT06854952Phase 2Updated Aug 10, 2026
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Overweight or Obesity
United States
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)Not Yet Recruiting
NCT07743164Phase 3Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruiting
NCT06731478Phase 3Updated Aug 10, 2026
Sponsor: Daiichi Sankyo
Gastric Cancer · Gastroesophageal Junction Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaCompleted
NCT05504720Phase 2Updated Aug 10, 2026
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophagogastric Adenocarcinoma
Germany
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC StudyTerminated
NCT04552704Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Tianhong Li
Advanced Malignant Solid Neoplasm
United States
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyRecruiting
NCT05879146Phase 2Updated Aug 10, 2026
Sponsor: M.D. Anderson Cancer Center
Tumor
United States
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Recruiting
NCT07499362Phase 2Updated Aug 10, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Tenosynovial Giant Cell Tumor
Japan
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)Recruiting
NCT06596694Phase 1, Phase 2Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastrointestinal Cancer
United States, Australia, Canada, Chile, China +10 more
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Recruiting
NCT06469944Phase 1, Phase 2Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +7 more
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung CancerAvailable
NCT07535359N/AUpdated Aug 7, 2026
Sponsor: Daiichi Sankyo
SCLC · Extensive-stage Small Cell Lung Cancer
United States
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)Active Not Recruiting
NCT05853367Phase 1Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Solid Tumors · Advanced Solid Tumors
United States, Canada, Chile, Israel, Poland +2 more
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruiting
NCT03618550Phase 2Updated Aug 7, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma · Relapsed or Refractory Hodgkin Lymphoma
United States
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Recruiting
NCT06136559Phase 3Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Australia, Belgium, Brazil, Canada +24 more
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Active Not Recruiting
NCT06459180Phase 3Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Australia, Austria, Belgium +27 more

Previous page Next page